Dr Reddy’s gets USFDA investigation conclusion report for Srikakulam manufactruring facility in Andhra Pradesh Kumar Jeetendra | May 8, 2020 Medication major Dr Reddy’s Laboratories on Friday said the US wellbeing controller has shut assessment of its assembling office in Srikakulam, Andhra Pradesh. The US Food and Drug Administration (USFDA) had given an admonition letter to the office in November, 2015, in the wake of assessing it in 2014. “We have gotten the foundation examination …
Dr Reddy’s Srikakulam Unit gets EIR from USFDA Kumar Jeetendra | May 14, 2020 Dr Reddy’s Laboratories said its details plant in Andhra Pradesh got the Establishment Inspection Report (EIR) from the US sedate controller. Dr Reddy’s Laboratories said that its Formulations Srikakulum Plant (SEZ) Unit I in Andhra Pradesh got the foundation review report (EIR) from US Food and Drug Administration (USFDA), demonstrating conclusion of the review. The …
Dr. Reddy’s ascents after Hyderabad office gets EIR from USFDA Kumar Jeetendra | May 20, 2020 Dr. Reddy’s Laboratories rose 0.71% to Rs 3725.7 after the organization said its definitions producing plant – 3 at Bachupally in Hyderabad got the foundation examination report (EIR) from US medicate controller. Dr. Reddy’s will report Q4 results today, 20 May 2020. The medication creator revealed a united total deficit of Rs 538.40 crore in …
Dr Reddy’s dispatches Avigan (Favipiravir) tablets in India Kumar Jeetendra | August 19, 2020 Dr Reddy’s Laboratories on August 19 announced the launch of Avigan (Favipiravir) pills, used for treating mild to moderate COVID-19 sufferers in India. Dr Reddy’s stated Avigan was approved by the Drugs Controller General of India (DCGI) for treating patients with moderate to medium COVID-19. “The need for high efficacy and quality, affordability and improved …
Dr Reddy’s’ settles case with Bristol Myers Squibb unit over nonexclusive malignant growth drug Kumar Jeetendra | September 17, 2020 The Hyderabad-based firm has settled litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb, Dr Reddy”s Laboratories said in a statement. In settlement of all outstanding claims in the litigation, Celgene has agreed to provide the company with a permit to sell volume-limited amounts of generic lenalidomide capsules in america starting on a confidential …
DRL gets DCGI s gesture to direct COVID-19 immunization stage 2/3 human preliminaries Kumar Jeetendra | October 17, 2020 Dr.Reddys Laboratories Ltd. and Russian Direct Investment Fund, Russias autonomous wealth fund, on Saturday announced they have received approval from the Drug Control General of India to conduct an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in India. The city-based drug maker said in a press release that this will be a …
Dr Reddy’s gets 3 perceptions from USFDA for US-based API plant Kumar Jeetendra | March 10, 2021 Dr Reddy’s Laboratories on Wednesday said the US health regulator has issued a Form 483 with three observations after inspecting its Production facility in Middleburg, New York. The audit of the business’s active pharmaceutical ingredients (API) manufacturing plant at Middleburg, New York has been completed from the US Food and Drug Administration (USFDA), the Hyderabad-based …
Rockwell Industries ties with DRL for freezer to store Sputnik V Kumar Jeetendra | June 9, 2021 Rockwell Industries, a cold chain appliance manufacturer on Wednesday announced its strategic partnership with Dr Reddy’s Labs, to provide its World Health Organisation – Performance, Quality and Safety certified Covid-19 vaccine freezersto enablestorage of Sputnik V vaccine in India. According to a release by Rockwell, the vaccine freezer plays a very critical role in the safety …
Pharma Majors Collaborate for Clinical Trial of Investigational Oral Anti-Viral Drug Molnupiravir for COVID-19 Kumar Jeetendra | June 29, 2021 India. June 29, 2021 – Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”), Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy’s”), Emcure Pharmaceuticals Limited (hereafter referred to as “Emcure”), Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, …
